Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Symptomatic and RT-PCR confirmed COVID-19 within 6 days from symptom onset.~2. Has any one of the following factors associated with disease progression:~   1. Elevated lactate dehydrogenase (LDH)~  2. Elevated C reactive protein (CRP)~  3. Lymphocyte count below normal limit~  4. Age 40 and above~  5. History of well-controlled diabetes, hypertension, chronic obstructive lung disease or ischemic heart diseases~  6. Stable chronic renal disease~  7. History of asthma~3. Disease outcome score of 6, 7 or 8 based on the COVID Scale~4. Willing to comply with the requirements of the study protocol and attend scheduled study visits~5. Can give written informed consent approved by the Ethical Review Board governing the site~Exclusion Criteria:~1. Aged below 21 years old~2. Female who is pregnant or breast-feeding~3. With the following conditions, but not limited to:~   1. Known or suspected congenital or acquired immunodeficiency; or receipt of immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or long-term systemic corticosteroid therapy defined as prednisone or equivalent for more than 2 consecutive weeks within the past 3 months~  2. Child-Pugh Class C chronic liver disease~  3. Renal insufficiency with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73m2 calculated by the CKD-EPI formula~  4. Suspected or confirmed active bacterial, fungal or mycobacterial infection~4. History of any allergic reaction to monoclonal antibodies~5. Currently enrolled in another COVID-19 investigational drug study~6. Previously enrolled in a COVID-19 investigational vaccine study~7. Any medical condition, which in the opinion of the Investigator, will compromise the safety of the patient

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- TY027 1,500 mg (Type: EXPERIMENTAL): 1,500 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
- TY027 2,000 mg (Type: EXPERIMENTAL): 2,000 mg of TY027 will be administered via IV infusion over a period of 30 minutes.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered via IV infusion over a period of 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).